Questions about big benefit seen at ESMO with AZ’s CD73, NKG2A mAbs
Combos outperform active control in NSCLC, but control flops versus past studies
Data from the Phase II COAST trial showed mAbs against two immuno-oncology targets — CD73 and NKG2A — led to big PFS benefits in NSCLC when combined with PD-L1 inhibitor Imfinzi durvalumab. But Imfinzi’s worse performance in the trial’s control arm versus previous clinical and real-world studies raises questions about how to interpret the combination data.
AstraZeneca plc (LSE:AZN; NASDAQ:AZN) presented the COAST data at the European Society of Medical Oncology (ESMO) Friday; the trial evaluated Imfinzi plus CD73 inhibitor oleclumab or Imfinzi plus NKG2A inhibitor monalizumab versus the active control of Imfinzi monotherapy in 189 patients with unresectable Stage III non-small cell lung cancer who had not progressed following chemoradiation therapy. ...